Login / Signup

Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2.

Martin BauerAnselm JordaValentin Al-JalaliMichael Wölfl-DuchekFelix BergmannAlina Nussbaumer-PröllAriane SteindlRomana GugenbergerSarah BischofDoris WimmerMarco IdzkoMarkus Zeitlinger
Published in: ERJ open research (2024)
The application of aerosolised APN01 is safe and well tolerated after single and multiple doses. By achieving a high local concentration in the lungs and low systemic bioavailability, inhaled rhACE2 may present a therapeutic option in ACE2-related diseases.
Keyphrases
  • recombinant human
  • open label
  • cystic fibrosis
  • angiotensin converting enzyme
  • angiotensin ii
  • randomized controlled trial